Evotec and CHDI Foundation extend Huntington's collaboration

Published: 14-Jan-2010
Research & Development

Evotec extends collaboration with CHDI Foundation through to the end of 2012


German drug discovery company Evotec has extended its collaboration with non-profit organisation CHDI Foundation through to the end of 2012.

The collaboration, which is aimed at finding new treatments for Huntington's disease, represents one of the largest joint innovation drug discovery CNS alliances within Evotec and will attract up to US$37.5m (Euro 25.9m) in research funding over the next three years.

Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography. Evotec has been providing research and innovation support to CHDI since 2006.

See more

You may also like

Research & Development

SynaptixBio and Evotec collaborate to develop novel antisense oligonucelotides for H-ABC

Read more
The companies will look to discover novel antisense oligonucleotides targeting mutant TUBB4A for the treatment of H-ABC

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

SynaptixBio and Evotec collaborate to develop novel antisense oligonucelotides for H-ABC

The companies will look to discover novel antisense oligonucleotides targeting mutant TUBB4A for the treatment of H-ABC
Research & Development

Pharma giants join £9.5 million dementia drug discovery collaboration

Johnson & Johnson Innovation, Takeda and Evotec have joined The Dementia Consortium
Research & Development

Galapagos expands fibrosis portfolio

Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development

Evotec and ABIVAX collaborate to develop novel antiviral agents

Evotec and ABIVAX have announced a strategic collaboration to discover and develop novel treatments for multiple viral infectious diseases
Media

Evotec to acquire Aptuit, expanding leadership in external innovation

Evotec and Aptuit have entered into a definitive agreement, Evotec will acquire Aptuit for US$ 300 million
Research & Development

Eternygen GmbH closes €8.0 million series A financing led by Epidarex Capital

Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, has announced the completion of its €8.0 million Series A funding round
Research & Development

Evotec and ex scientia join forces to discover bispecific small molecule immuno-oncology therapeutics

Initial focus will be cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology
Subscribe now